SMART Watch Facilitated Early Discharge in Patients Undergoing Transcatheter Aortic Valve Replacement

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Jun 30, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how well a special watch, called the HUAWEI Watch, can help monitor the health of patients who have undergone a procedure called Transcatheter Aortic Valve Replacement (TAVR) for a heart condition known as aortic stenosis. The watch will track important health information such as heart rates, oxygen levels, daily activities, and sleep patterns. Researchers want to see if this technology can provide early warnings about any changes in a patient's health after their procedure, especially in the context of a new protocol that allows patients to leave the hospital sooner.

To participate in this study, individuals must be at least 18 years old and willing to give their consent. They should have severe aortic stenosis and be scheduled for an elective TAVR procedure. However, those with serious complications from TAVR, certain life-threatening conditions, or severe dementia will not be eligible. Participants will wear the HUAWEI Watch and will be monitored during their recovery, helping to ensure their safety and well-being as they adjust at home. This study aims to improve patient outcomes and make the recovery process smoother.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • At least 18 years old;
• • Be willing and able to provide informed consent to participate in the study;
• • Not share HUAWEI Watch, HUAWEI phone with anyone else;
• • Patient has severe aortic stenosis with echocardiographically derived criteria: mean gradient \> 40mmHg or maximum velocity greater than 4.0 m/s or an initial aortic valve area of \< 1.0 cm2;
• • Patient who undergoing elective transfemoral transcatheter aortic valve replacement.
• Exclusion Criteria:
• • Severe complications of TAVR, such as death, and conversion to SAVR;
• • Life expectancy is less than 12 months due to non-heart disease (such as cancer, chronic liver disease, chronic kidney disease, or chronic end-stage lung disease, etc.);
• • Severe dementia (cannot sign research informed consent, cannot take care of themselves or complete the study visit);
• • The investigator believes that the patient is not suitable to participate in the study or complete the follow-up prescribed by the protocol from other medical, social and psychological aspects;
• • The patient is currently participating in another randomized study.